Register now to learn how NGS is informing oncology drug discovery

Genetic sequencing in the lab

Join this free webinar to learn about the biggest challenges and opportunities facing the next-generation sequencing (NGS) oncology space.

Hosted by DDW and supported by Tecan, “How next-generation sequencing is informing oncology drug discovery” will be free to attend on April 24 at 7AM PST / 10AM EST / 3PM BST / 4PM CET.  

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Also presenting is Dr Steve SheardownHead of Molecular Biology and Cell Engineering at Cerevance.

In his presentation, Darrell Green will tell a personal story about why he investigates primary bone cancer, shares why commercial kits used for small RNA NGS studies are biased and how to reduce the bias to reveal novel small RNAs, and explains why and how these new small RNAs are investigated at the molecular level, which leads to new drug development.  

Panna Sharma will discuss some of the use-cases of NGS in developing oncology targets and the benefits and challenges we’re seeing in regard to the technology’s use.  

NGS has transformed the genomics market from basic research to the clinic, and so Dr Budel and Dr Edwards’ presentation will focus on the pivotal role NGS plays at various developmental stages in biopharma, most notably in oncology.  

Dr Sheardown will discuss Cerevance’s work in producing comprehensive transcriptional profiles of specific brain cell types and how it has used the Trio RNA-Seq Library Preparation Kit with Tecan’s DreamPrep NGS automation to generate good data from difficult materials.

This webinar will answer the following questions:  

  • How is NGS being used to find new drugs to treat cancer? 
  • Can NGS increase the chances of an oncology drug making it to market?  
  • Can NGS identify previously undruggable targets in cancer?  
  • How can the technology best be implemented in research labs?  
  • Will NGS help drive personalised cancer therapies?  
  • Can NGS technology help direct patients towards suitable clinical trials?

Register now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free